How Innovent Biologics Achieved Global Clinical Trial Leadership: Case Study

Innovent Biologics, Inc. (HKEX: 01801) has established itself as one of China’s most successful biopharmaceutical companies, and a central pillar of that success has been its systematic approach to global clinical trial leadership. Founded in 2011 by Dr. Michael Yu (formerly of Eli Lilly), Innovent has grown from a Suzhou-based startup to a fully integrated biopharmaceutical company with 10+ marketed products, a pipeline of over 30 clinical-stage candidates, and a track record of conducting clinical trials that meet the highest global standards — including acceptance by the US FDA, the European Medicines Agency (EMA), and Japan’s PMDA.

This case study examines the specific strategies, investments, and capabilities Innovent built to achieve global clinical trial leadership — and what other biotech companies, both domestic and foreign, can learn from its approach.

The Starting Point: From Biosimilars to Global Innovation

Innovent’s early clinical strategy was pragmatic and focused on China’s domestic market. Its first major product, Tyvyt (sintilimab), a PD-1 inhibitor, was developed primarily for the Chinese market through a strategic partnership with Eli Lilly. By 2018, sintilimab received NMPA approval for relapsed/refractory classical Hodgkin’s lymphoma, and Innovent had demonstrated its ability to conduct high-quality clinical trials within China.

However, the company recognized early that long-term success required global capabilities. The China biotech market was becoming crowded — by 2019, over 20 PD-1/PD-L1 inhibitors were in development in China alone. Competing solely on domestic approvals would lead to pricing pressure (with NRDL negotiations driving PD-1 prices down by 60–80%). The strategic response was to build clinical trial capabilities that would allow Innovent to:

• Generate data acceptable to multiple global regulators simultaneously
• Participate in registrational trials for international markets
• License its pipeline assets to global partners at premium valuations
• Compete for global investigator-initiated trials and academic collaborations

Building Global Clinical Trial Infrastructure

Investment in GCP-Compliant Trial Sites

Innovent’s first major infrastructure investment was in building clinical trial sites across China that met ICH E6 (R2) Good Clinical Practice standards — the global benchmark accepted by the FDA, EMA, and PMDA. Rather than waiting for international partners to request GCP-compliant sites, Innovent proactively certified its investigator network:

• Established a central clinical operations team based in Suzhou and Shanghai, with dedicated regional monitoring teams across 30+ Chinese cities
• Implemented electronic trial master file (eTMF) systems compatible with FDA 21 CFR Part 11 requirements
• Invested in risk-based monitoring (RBM) infrastructure, reducing source data verification costs by 30–40% while improving data quality
• Trained over 500 clinical trial investigators at partner hospitals on ICH GCP standards, with annual re-certification

By 2023, Innovent had over 200 active clinical trial sites across China, all operating to global GCP standards — one of the largest and most sophisticated investigator networks of any China-based biotech company.

International Trial Integration

Innovent did not limit its global ambitions to China-based sites. The company actively sought to integrate its Chinese clinical sites into global multi-regional clinical trials (MRCTs). The key milestones in this strategy included:

Key Clinical Trial Achievements

ORIENT-11: The Landmark Sintilimab Trial

The ORIENT-11 trial — a randomized, double-blind Phase III study evaluating sintilimab in combination with pemetrexed and platinum-based chemotherapy for first-line non-squamous non-small cell lung cancer (NSCLC) — became a defining moment for Innovent’s global clinical trial credibility. The trial enrolled 397 patients across 42 Chinese sites and demonstrated a significant improvement in progression-free survival and overall survival versus chemotherapy alone.

What made ORIENT-11 significant for global regulatory acceptance was its design:

• The protocol was designed in consultation with both the CDE and FDA to ensure mutual acceptance of endpoints
• Primary endpoint (progression-free survival by independent radiologic review) used RECIST 1.1 criteria — the global standard
• Data management and statistical analysis followed ICH E9 statistical principles
• The independent data monitoring committee (IDMC) included international experts

Although the FDA ultimately issued a Complete Response Letter (CRL) for sintilimab in 2022 requesting additional manufacturing data (not clinical data), the trial’s clinical design and data quality were not questioned — a testament to the rigor of Innovent’s clinical operations. The company addressed the manufacturing concerns by 2023 and refiled.

IBI-112 (PCSK9): First Domestic PCSK9 Monoclonal Antibody

Innovent’s IBI-112 (tafolecimab) — a PCSK9 inhibitor for hypercholesterolemia — demonstrated the power of the company’s clinical trial network to generate robust data quickly. The Phase III CREDIT series of trials enrolled over 1,500 patients across 60+ Chinese sites in under 18 months — an enrollment speed that would be difficult to replicate in most other countries. The trials employed:

• Centralized lipid testing at a CAP-accredited central laboratory
• Electronic case report forms with real-time data quality checks
• Monthly investigator meetings to ensure consistent enrollment criteria application

Tafolecimab was approved by the NMPA in 2023, becoming the first domestically developed PCSK9 inhibitor in China and demonstrating that Innovent’s clinical trial infrastructure could support cardiovascular outcomes trials — which typically require large patient numbers and long follow-up periods.

IBI-188 (CD47): Global Differentiation Trial

Innovent’s IBI-188 (lemzoparlimab) program — a CD47 inhibitor for myelodysplastic syndrome (MDS) — represented the company’s most ambitious global clinical trial strategy. The program was particularly challenging because CD47 was a crowded target (with competitors including Forty Seven/Magenta, Arch Oncology, ALX Oncology, and Trillium Therapeutics), and Innovent needed to differentiate its candidate through clinical trial design.

The solution was a global Phase Ib/II trial simultaneously enrolling in China, the US, and Australia — one of the first truly global early-stage clinical programs conducted by a China-based biotech company. By demonstrating comparable safety and efficacy across Asian and non-Asian populations, Innovent was able to:

• Decouple the program from China-specific development risk
• Generate data suitable for both NMPA and FDA regulatory discussions
• Attract global licensing interest at a premium valuation

While lemzoparlimab’s clinical development faced competition-related challenges, the trial infrastructure and cross-border operational capabilities established during this program became a template for later pipeline assets.

Quality Systems and Regulatory Compliance

Global clinical trial leadership is impossible without a quality management system that satisfies multiple regulators simultaneously. Innovent built its quality systems to meet the highest common denominator of regulatory requirements — meaning that if a trial was acceptable to the FDA, it would automatically be acceptable to the NMPA, EMA, and PMDA. Key components included:

Clinical Quality Management System (CQMS)

Innovent developed a CQMS aligned with ICH E6 (R2) and FDA 21 CFR Part 312, covering:

• Centralized IRB/EC submission tracking across 200+ sites
• Automated serious adverse event (SAE) reconciliation between clinical and safety databases
• Risk-based quality management with centralized statistical monitoring
• Third-party audit program for all CRO partners and clinical sites

Data Integrity and 21 CFR Part 11 Compliance

Innovent invested in electronic data capture (EDC) systems validated for 21 CFR Part 11 compliance, with:

• Audit trails for all data changes
• Electronic signatures with two-factor authentication
• Real-time discrepancy detection and query management
• Data backups in geographically separated data centers

Supply Chain for Clinical Trial Materials

Global clinical trials require reliable supply of investigational product. Innovent established:

• GMP-certified manufacturing facilities in Suzhou capable of producing clinical-grade antibody drug substance and drug product
• Temperature-controlled logistics partnerships for distribution to US, EU, and Australian trial sites
• Impression and blinding capabilities compliant with FDA and EMA requirements for double-blind trials
• Inventory management systems capable of supporting multiple concurrent global trials

Strategic Partnerships as a Force Multiplier

Innovent’s clinical trial leadership was not built in isolation. Strategic partnerships played a critical role in accelerating capability building:

• Eli Lilly (2015–present): The partnership with Lilly provided early-stage expertise in global regulatory standards for oncology clinical trials. Lilly’s quality requirements pushed Innovent’s clinical operations to global standards from the outset
• Hutchison MediPharma (2020): Clinical trial collaboration for combination therapies in oncology, expanding Innovent’s experience with targeted therapy combinations
• MD Anderson Cancer Center (2021): Academic research collaboration that provided access to world-class clinical trial design expertise and international investigator network
• Coherus BioSciences (2022): Commercial partnership for sintilimab in the US market, with Coherus providing FDA regulatory affairs expertise

Each partnership brought not just financial resources but specific regulatory and clinical capabilities that accelerated Innovent’s learning curve. The company was deliberate about structuring partnerships to include hands-on knowledge transfer, not just licensing agreements.

Measurable Outcomes

Innovent’s investment in global clinical trial leadership produced tangible results:

• 10+ marketed products in China as of 2025, spanning oncology, autoimmune diseases, cardiovascular medicine, and metabolic disorders
• 30+ clinical-stage pipeline assets in China, with 6 in global registrational trials
• 5 FDA IND acceptances with trials enrolling patients in the US
• 2 EMA regulatory filings (via partners)
• Global licensing deals valued at over $1 billion in upfront and milestone payments
• Average clinical trial enrollment speed 2x faster than US-only sites for comparable trials
• Over 500 patients enrolled in global multi-regional clinical trials (non-Chinese sites)

Key Lessons for Biotech Companies Seeking Global Clinical Trial Leadership

1. Build for global standards from day one. Innovent invested in ICH GCP-compliant infrastructure before it was required by its partners or regulators — this proved prescient when the company later sought FDA approvals
2. Design trials for regulatory reciprocity. ORIENT-11’s protocol was designed from the outset to be acceptable to both the CDE and FDA. Retrofitting a China-only trial for international acceptance is more expensive and riskier
3. Invest in data quality infrastructure. The FDA’s CRL for sintilimab was about manufacturing, not clinical data — proof that the clinical data quality was never questioned. This required significant investment in EDC systems, quality management, and audit programs
4. Use partnerships strategically. Each partnership should have a specific capability-building objective beyond capital. Innovent’s partnerships with Lilly, Coherus, and MD Anderson each filled a different gap in clinical trial expertise
5. Plan for manufacturing from the start. Global clinical trials require global-quality drug supply. GMP-compliant manufacturing should be part of the clinical development plan, not an afterthought
6. Regulatory authorities value China-generated data. When generated to global standards, Chinese clinical data is increasingly accepted by the FDA and EMA for regulatory decisions — but only when the trial design, conduct, and data management meet the highest standards

Key Takeaway

Related Resources

• ICH E6 (R2): Good Clinical Practice standards for clinical trial conduct
• ICH E9: Statistical principles for clinical trials
• FDA 21 CFR Part 11: Electronic records and electronic signature requirements
• NMPA Administrative Measures for Drug Registration (2020): China’s framework for clinical trial approval and registration
• CDE Technical Guidelines for Multi-Regional Clinical Trials (2019): CDE guidance on MRCT design and acceptance criteria